Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Serous macrophages pack Bhlhe40 for a randonnée.

Rothlin CV, Ghosh S.

Nat Immunol. 2019 Jun;20(6):670-671. doi: 10.1038/s41590-019-0373-6. No abstract available.

PMID:
31061527
2.

Induction of sterile type 2 inflammation.

de Kouchkovsky DA, Ghosh S, Rothlin CV.

Nat Mater. 2019 Mar;18(3):193-194. doi: 10.1038/s41563-019-0300-0. No abstract available.

PMID:
30783225
3.

Cenabis Bene: Treg Cells Invite Macrophages to Dine.

Hughes LD, Ghosh S, Rothlin CV.

Immunity. 2018 Oct 16;49(4):579-582. doi: 10.1016/j.immuni.2018.10.002.

PMID:
30332622
4.

Coagulopathies and inflammatory diseases: '…glimpse of a Snark'.

Del Carmen S, Hapak SM, Ghosh S, Rothlin CV.

Curr Opin Immunol. 2018 Dec;55:44-53. doi: 10.1016/j.coi.2018.09.005. Epub 2018 Sep 27. Review.

PMID:
30268838
5.

Axon Regeneration: Antagonistic Signaling Pairs in Neuronal Polarization.

Hapak SM, Ghosh S, Rothlin CV.

Trends Mol Med. 2018 Jul;24(7):615-629. doi: 10.1016/j.molmed.2018.05.007. Epub 2018 Jun 19. Review.

PMID:
29934283
6.

PAR3-PAR6-atypical PKC polarity complex proteins in neuronal polarization.

Hapak SM, Rothlin CV, Ghosh S.

Cell Mol Life Sci. 2018 Aug;75(15):2735-2761. doi: 10.1007/s00018-018-2828-6. Epub 2018 Apr 25. Review.

PMID:
29696344
7.

Antiphospholipid Antibodies Inhibit Trophoblast Toll-Like Receptor and Inflammasome Negative Regulators.

Mulla MJ, Weel IC, Potter JA, Gysler SM, Salmon JE, Peraçoli MTS, Rothlin CV, Chamley LW, Abrahams VM.

Arthritis Rheumatol. 2018 Jun;70(6):891-902. doi: 10.1002/art.40416. Epub 2018 Apr 25.

8.

Chronicles of Cell Death Foretold: Specificities in the Mechanism of Disposal.

Hughes LD, Bosurgi L, Ghosh S, Rothlin CV.

Front Immunol. 2017 Dec 11;8:1743. doi: 10.3389/fimmu.2017.01743. eCollection 2017. Review.

9.

Erythrocyte efferocytosis modulates macrophages towards recovery after intracerebral hemorrhage.

Chang CF, Goods BA, Askenase MH, Hammond MD, Renfroe SC, Steinschneider AF, Landreneau MJ, Ai Y, Beatty HE, da Costa LHA, Mack M, Sheth KN, Greer DM, Huttner A, Coman D, Hyder F, Ghosh S, Rothlin CV, Love JC, Sansing LH.

J Clin Invest. 2018 Feb 1;128(2):607-624. doi: 10.1172/JCI95612. Epub 2017 Dec 18.

10.

Death begets a new beginning.

Bosurgi L, Hughes LD, Rothlin CV, Ghosh S.

Immunol Rev. 2017 Nov;280(1):8-25. doi: 10.1111/imr.12585. Review.

11.

Viral Infection Sensitizes Human Fetal Membranes to Bacterial Lipopolysaccharide by MERTK Inhibition and Inflammasome Activation.

Cross SN, Potter JA, Aldo P, Kwon JY, Pitruzzello M, Tong M, Guller S, Rothlin CV, Mor G, Abrahams VM.

J Immunol. 2017 Oct 15;199(8):2885-2895. doi: 10.4049/jimmunol.1700870. Epub 2017 Sep 15.

12.

The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer.

Uribe DJ, Mandell EK, Watson A, Martinez JD, Leighton JA, Ghosh S, Rothlin CV.

PLoS One. 2017 Jul 20;12(7):e0179979. doi: 10.1371/journal.pone.0179979. eCollection 2017.

13.

Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with apoptotic cells.

Bosurgi L, Cao YG, Cabeza-Cabrerizo M, Tucci A, Hughes LD, Kong Y, Weinstein JS, Licona-Limon P, Schmid ET, Pelorosso F, Gagliani N, Craft JE, Flavell RA, Ghosh S, Rothlin CV.

Science. 2017 Jun 9;356(6342):1072-1076. doi: 10.1126/science.aai8132. Epub 2017 May 11.

14.

Phagocytosis imprints heterogeneity in tissue-resident macrophages.

A-Gonzalez N, Quintana JA, García-Silva S, Mazariegos M, González de la Aleja A, Nicolás-Ávila JA, Walter W, Adrover JM, Crainiciuc G, Kuchroo VK, Rothlin CV, Peinado H, Castrillo A, Ricote M, Hidalgo A.

J Exp Med. 2017 May 1;214(5):1281-1296. doi: 10.1084/jem.20161375. Epub 2017 Apr 21.

15.

TAM Receptors Are Not Required for Zika Virus Infection in Mice.

Hastings AK, Yockey LJ, Jagger BW, Hwang J, Uraki R, Gaitsch HF, Parnell LA, Cao B, Mysorekar IU, Rothlin CV, Fikrig E, Diamond MS, Iwasaki A.

Cell Rep. 2017 Apr 18;19(3):558-568. doi: 10.1016/j.celrep.2017.03.058.

16.

IGF1 Shapes Macrophage Activation in Response to Immunometabolic Challenge.

Spadaro O, Camell CD, Bosurgi L, Nguyen KY, Youm YH, Rothlin CV, Dixit VD.

Cell Rep. 2017 Apr 11;19(2):225-234. doi: 10.1016/j.celrep.2017.03.046.

17.

TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.

Akalu YT, Rothlin CV, Ghosh S.

Immunol Rev. 2017 Mar;276(1):165-177. doi: 10.1111/imr.12522. Review.

18.

Negative Regulation of Type 2 Immunity.

de Kouchkovsky DA, Ghosh S, Rothlin CV.

Trends Immunol. 2017 Mar;38(3):154-167. doi: 10.1016/j.it.2016.12.002. Epub 2017 Jan 9. Review.

19.

AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity.

Schmid ET, Pang IK, Carrera Silva EA, Bosurgi L, Miner JJ, Diamond MS, Iwasaki A, Rothlin CV.

Elife. 2016 Jun 28;5. pii: e12414. doi: 10.7554/eLife.12414.

20.

TAM receptors regulate multiple features of microglial physiology.

Fourgeaud L, Través PG, Tufail Y, Leal-Bailey H, Lew ED, Burrola PG, Callaway P, Zagórska A, Rothlin CV, Nimmerjahn A, Lemke G.

Nature. 2016 Apr 14;532(7598):240-244. doi: 10.1038/nature17630. Epub 2016 Apr 6.

21.

The TAM family receptor tyrosine kinase TYRO3 is a negative regulator of type 2 immunity.

Chan PY, Carrera Silva EA, De Kouchkovsky D, Joannas LD, Hao L, Hu D, Huntsman S, Eng C, Licona-Limón P, Weinstein JS, Herbert DR, Craft JE, Flavell RA, Repetto S, Correale J, Burchard EG, Torgerson DG, Ghosh S, Rothlin CV.

Science. 2016 Apr 1;352(6281):99-103. doi: 10.1126/science.aaf1358.

22.

The Wnt Antagonist Dickkopf-1 Promotes Pathological Type 2 Cell-Mediated Inflammation.

Chae WJ, Ehrlich AK, Chan PY, Teixeira AM, Henegariu O, Hao L, Shin JH, Park JH, Tang WH, Kim ST, Maher SE, Goldsmith-Pestana K, Shan P, Hwa J, Lee PJ, Krause DS, Rothlin CV, McMahon-Pratt D, Bothwell AL.

Immunity. 2016 Feb 16;44(2):246-58. doi: 10.1016/j.immuni.2016.01.008. Epub 2016 Feb 9.

23.

Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation.

Bárcena C, Stefanovic M, Tutusaus A, Joannas L, Menéndez A, García-Ruiz C, Sancho-Bru P, Marí M, Caballeria J, Rothlin CV, Fernández-Checa JC, de Frutos PG, Morales A.

J Hepatol. 2015 Sep;63(3):670-8. doi: 10.1016/j.jhep.2015.04.013. Epub 2015 Apr 20.

24.

MERTK as negative regulator of human T cell activation.

Cabezón R, Carrera-Silva EA, Flórez-Grau G, Errasti AE, Calderón-Gómez E, Lozano JJ, España C, Ricart E, Panés J, Rothlin CV, Benítez-Ribas D.

J Leukoc Biol. 2015 Apr;97(4):751-60. doi: 10.1189/jlb.3A0714-334R. Epub 2015 Jan 26.

25.

TAM receptor signaling in immune homeostasis.

Rothlin CV, Carrera-Silva EA, Bosurgi L, Ghosh S.

Annu Rev Immunol. 2015;33:355-91. doi: 10.1146/annurev-immunol-032414-112103. Epub 2015 Jan 14. Review.

26.

Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma.

Kusne Y, Carrera-Silva EA, Perry AS, Rushing EJ, Mandell EK, Dietrich JD, Errasti AE, Gibbs D, Berens ME, Loftus JC, Hulme C, Yang W, Lu Z, Aldape K, Sanai N, Rothlin CV, Ghosh S.

Sci Signal. 2014 Aug 12;7(338):ra75. doi: 10.1126/scisignal.2005196.

27.

Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer.

Rothlin CV, Leighton JA, Ghosh S.

Inflamm Bowel Dis. 2014 Aug;20(8):1472-80. doi: 10.1097/MIB.0000000000000050. Review.

28.

Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors.

Bhattacharyya S, Zagórska A, Lew ED, Shrestha B, Rothlin CV, Naughton J, Diamond MS, Lemke G, Young JA.

Cell Host Microbe. 2013 Aug 14;14(2):136-47. doi: 10.1016/j.chom.2013.07.005.

29.

Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer.

Bosurgi L, Bernink JH, Delgado Cuevas V, Gagliani N, Joannas L, Schmid ET, Booth CJ, Ghosh S, Rothlin CV.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13091-6. doi: 10.1073/pnas.1302507110. Epub 2013 Jul 22.

30.

T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response.

Carrera Silva EA, Chan PY, Joannas L, Errasti AE, Gagliani N, Bosurgi L, Jabbour M, Perry A, Smith-Chakmakova F, Mucida D, Cheroutre H, Burstyn-Cohen T, Leighton JA, Lemke G, Ghosh S, Rothlin CV.

Immunity. 2013 Jul 25;39(1):160-70. doi: 10.1016/j.immuni.2013.06.010. Epub 2013 Jul 11.

31.

Therapeutic efficacy of Tyro3, Axl, and Mer tyrosine kinase agonists in collagen-induced arthritis.

van den Brand BT, Abdollahi-Roodsaz S, Vermeij EA, Bennink MB, Arntz OJ, Rothlin CV, van den Berg WB, van de Loo FA.

Arthritis Rheum. 2013 Mar;65(3):671-80. doi: 10.1002/art.37786.

32.

TAM receptor signaling and autoimmune disease.

Rothlin CV, Lemke G.

Curr Opin Immunol. 2010 Dec;22(6):740-6. doi: 10.1016/j.coi.2010.10.001. Epub 2010 Oct 26. Review.

33.

Immunobiology of the TAM receptors.

Lemke G, Rothlin CV.

Nat Rev Immunol. 2008 May;8(5):327-36. doi: 10.1038/nri2303. Review.

34.

TAM receptors are pleiotropic inhibitors of the innate immune response.

Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G.

Cell. 2007 Dec 14;131(6):1124-36.

35.

Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival.

Ghosh S, Tergaonkar V, Rothlin CV, Correa RG, Bottero V, Bist P, Verma IM, Hunter T.

Cancer Cell. 2006 Sep;10(3):215-26.

36.

TAM receptor function in the retinal pigment epithelium.

Prasad D, Rothlin CV, Burrola P, Burstyn-Cohen T, Lu Q, Garcia de Frutos P, Lemke G.

Mol Cell Neurosci. 2006 Sep;33(1):96-108. Epub 2006 Aug 9.

PMID:
16901715
37.

Twist mediates suppression of inflammation by type I IFNs and Axl.

Sharif MN, Sosic D, Rothlin CV, Kelly E, Lemke G, Olson EN, Ivashkiv LB.

J Exp Med. 2006 Aug 7;203(8):1891-901. Epub 2006 Jul 10.

38.

Effects of quinine, quinidine, and chloroquine on alpha9alpha10 nicotinic cholinergic receptors.

Ballestero JA, Plazas PV, Kracun S, Gómez-Casati ME, Taranda J, Rothlin CV, Katz E, Millar NS, Elgoyhen AB.

Mol Pharmacol. 2005 Sep;68(3):822-9. Epub 2005 Jun 13.

PMID:
15955868
39.

Direct interaction of serotonin type 3 receptor ligands with recombinant and native alpha 9 alpha 10-containing nicotinic cholinergic receptors.

Rothlin CV, Lioudyno MI, Silbering AF, Plazas PV, Casati ME, Katz E, Guth PS, Elgoyhen AB.

Mol Pharmacol. 2003 May;63(5):1067-74.

PMID:
12695535
40.

alpha10: a determinant of nicotinic cholinergic receptor function in mammalian vestibular and cochlear mechanosensory hair cells.

Elgoyhen AB, Vetter DE, Katz E, Rothlin CV, Heinemann SF, Boulter J.

Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3501-6. Epub 2001 Mar 6.

41.

Block of the alpha9 nicotinic receptor by ototoxic aminoglycosides.

Rothlin CV, Katz E, Verbitsky M, Vetter DE, Heinemann SF, Elgoyhen AB.

Neuropharmacology. 2000 Oct;39(13):2525-32.

PMID:
11044724
42.

Mixed nicotinic-muscarinic properties of the alpha9 nicotinic cholinergic receptor.

Verbitsky M, Rothlin CV, Katz E, Elgoyhen AB.

Neuropharmacology. 2000 Oct;39(13):2515-24.

PMID:
11044723
43.

High calcium permeability and calcium block of the alpha9 nicotinic acetylcholine receptor.

Katz E, Verbitsky M, Rothlin CV, Vetter DE, Heinemann SF, Elgoyhen AB.

Hear Res. 2000 Mar;141(1-2):117-28.

PMID:
10713500
44.

Supplemental Content

Loading ...
Support Center